Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker

• US 5,083,563 A
• Filed: 02/16/1990
• Issued: 01/28/1992
• Est. Priority Date: 02/16/1990
• Status: Expired due to Term

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Telectronics Pacing Systems, Inc (Abbott Laboratories Incorporated)
• Inventors: Collins, Kenneth A.
• Primary Examiner(s): Kamm, William E.
• Assistant Examiner(s): Schaetzle, Kennedy J.
• Application Number:
  US07/481,364
• Time in Patent Office: 711 Days
• Field of Search: 128/419 PG, 128/672, 128/673, 128/419 D
• US Class Current: 607/4
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/36564 controlled by blood pressure
• CPC Class Codes: A61N 1/39622 Pacing therapy

Abstract

A cardioverting/defibrillating pacemaker with the ability to sense and respond to haemodynamic compromise. The ventricular pressure (VP) and electrical activity of the heart are sensed via one or more transvenous or epicardial devices. The filtered peak-to-peak amplitude (VFPPA) or a peak pressure function (VPPF) based upon the right and/or left VP waveform(s) are derived. In one embodiment the VP and the electrical activity of the heart are sensed and processed continuously, and the VFPPA or the VPPF continuously derived. The VFPPA or the VPPF, and the ECG are used to initiate bradycardia pacing, antitachycardia pacing and cardioversion/defibrillation therapies. In another embodiment the VP and electrical activity of the heart are continuously sensed. The electrical activity is processed continuously and used to determine whether or not some irregularity exists. If so, one of the VPPF or VFPPA is derived and used to decide which of the therapies are to be used. One of the VPPF or VFPPA is also periodically determined to ensure optimal haemodynamic function. In both emobidments the degree of haemodynamic compromise is determined by comparing the derived VFPPA or VPPF with programmed values. An algorithm maximizes the effectiveness of support pacing. Preferably an ECG transvenous sensor in the right atrium and a combined ECG/VP sensor in the right ventricle are used.

Claims

1. An apparatus for the treatment of the heart, comprising:

a) means for obtaining an electrogram from the heart;

b) means for acquiring a signal indicative of ventricular pressure;

c) processing means for processing said signal to produce a signal representative of at least one of filtered peak-to-peak ventricular pressure amplitude and ventricular peak pressure function, the latter comprising the integral of a filtered and rectified ventricular pressure waveform signal;

d) comparison means responsive to said representative signal for determining whether at least one of said filtered peak-to-peak ventricular pressure amplitude and said ventricular peak pressure function is below a predetermined level;

e) examining means for examining said electrogram to determine whether an arrhythmia is present;

f) therapy selection means responsive to said comparison means and said examining means for selecting therapy to apply to the heart if at least one of said filtered peak-to-peak ventricular pressure amplitude and said ventricular peak pressure function is below said predetermined level and an arrhythmia is present; and

g) therapy application means for applying a therapy to the heart.

2. The apparatus of claim 1 wherein said processing means includes means for removing changes in baseline level of said signal indicative of ventricular pressure.

3. The apparatus of claim 1 wherein said processing means includes means for removing low frequency components in said signal indicative of ventricular pressure.

4. The apparatus of claim 3, wherein said means for removing low frequency components is a high pass filter.

5. The apparatus of claim 4, wherein said high pass filter has a -3 dB point in the range of 0.1 to 0.5 Hz.

6. The apparatus of claim 3 wherein said means for removing low frequency components is a bandpass filter.

7. The apparatus of claim 1, wherein said processing means comprises:

filter means for filtering said signal indicative of ventricular pressure to produce a filtered signal;

rectifier means for rectifying said filtered signal to produce a rectified signal; and

integration means for integrating the filtered, rectified signal to produce said ventricular peak pressure function.

8. The apparatus of claim 1, wherein said processing means comprises:

filter means for filtering said signal indicative of ventricular pressure to produce a filtered signal;

means for determining a minimum value of said filtered signal;

means for determining a maximum value of said filtered signal; and

means for determining a difference between said minimum value and said maximum value to define a peak-to-peak amplitude of said filtered signal, whereby said processing means produces a signal representative of said filtered peak-to-peak ventricular pressure amplitude.

9. The apparatus of claim 1, wherein said electrogram and said ventricular pressure are continuously sensed;

and wherein said processing means continuously produces said representative signal.

10. The apparatus of claim 1, wherein said electrogram is continuously sensed, and wherein said processing means produces said representative signal only when an arrhythmia is indicated by the electrogram.

11. The apparatus of claim 1, wherein said therapy selection means responds to a bradycardia, and said therapy means includes a pacing means and a pacing optimization algorithm for optimizing pacing so as to produce an increase in at least one of filtered ventricular peak-to-peak pressure amplitude and ventricular peak pressure function.

12. The apparatus of claim 10, wherein said pacing optimization algorithm selects various values of heart rate and A-V delay.

13. The apparatus of claim 1, wherein said comparison means comprises a counter responsive to amplitude of said representative signal, said counter being reset if said amplitude reaches a predetermined level, said counter counting up if said amplitude does not reach a predetermined level;

and means for ascertaining when the count in said counter reaches a predetermined value, and to then provide an input to said therapy selection means indicating that therapy is required.

14. The apparatus of claim 1, wherein said comparison means comprises:

means for storing values of amplitude of representative signals derived from Y successive heart beats, and means for determining whether X of the stored amplitudes are below a predetermined value; and

to then provide an input to said therapy selection means indicating that therapy is required.

15. An apparatus for the treatment of a malfunctioning heart comprising:

a programmable device capable of sensing malfunction of the heart and the successful treatment of malfunction based on electrical and haemodynamic function of the heart;

means for calculating a filtered peak-to-peak amplitude and a filtered and rectified integration of a pressure waveform of the right ventricle;

means for determining haemodynamic compromise based upon the calculations;

first therapy means for initiating anti-tachycardia pacing and cardioversion/defibrillation based on the electrical and haemodynamic function of the heart; and

second therapy means for implementing a method of bradycardia support pacing optimization based on both the electrical and the haemodynamic function of the heart.

16. The apparatus of claim 15 further comprising means for warning at least one of a recipient of the device and the recipient'"'"'s clinician of failure of said method.

17. The apparatus of claim 15 wherein at least one of the pressure waveform of the left ventricle, the right atrium and the left atrium is used instead of, or in conjunction with, that of the right ventricle.

18. The apparatus of claim 15 wherein sensing of electrical activity of the heart and electrical stimulation of the heart is done in at least one of the right atrium, the right ventricle, the left atrium and the left ventricle.

19. The apparatus of claim 15 wherein said second therapy means is rate responsive.

20. A method of determining an index of the hemodynamic function of the heart by monitoring right ventricular pressure to obtain a pressure waveform comprising the steps of:

high-pass filtering the pressure waveform and determining the peak-to-peak amplitude from the filtered pressure waveform to determine an index of hemodynamic function;

or, filtering and rectifying said pressure waveform and then integrating the filtered and rectified waveform to produce a peak pressure function representative of said hemodynamic index.

21. The method of claim 20, wherein said monitoring is implemented continuously.

22. The method of claim 20, wherein said monitoring is implemented intermittently.

23. The method of claim 20 wherein a pressure waveform of at least one of the left ventricle, the right atrium and the left atrium is used instead of, or in conjunction with, that of the right ventricle.

24. A method of automatically optimizing bradycardia support pacing by monitoring the haemodynamic performance of the heart comprising the steps of:

sensing the haemodynamic state of the heart by monitoring right ventricular pressure, wherein said step of sensing the haemodynamic state further comprises processing the right ventricular pressure waveform by either high-pass filtering said pressure waveform and determining the peak-to-peak amplitude of said filtered pressure waveform;

or, filtering and rectifying said pressure waveform and then integrating the filtered and rectified waveform to produce a peak pressure function

determining that the sensed haemodynamic state is outside programmed performance limits, that there is a relatively steady cardiac state present, and that there is not a tachyarrhythmia present;

sweeping through programmed pacing parameter values including at least one of A-V delay and pacing rate in a step wise pattern;

reassessing the heart'"'"'s haemodynamic state and electrical activity after each change in pacing parameters; and

choosing, out of those pacing parameters tested, ones that produce the best haemodynamic state.

25. The method of claim 24 further comprising warning at least one of a recipient of the device and the recipient'"'"'s clinician of failure of the method.

26. The method of claim 24 wherein said monitoring is implemented continuously.

27. The method of claim 24 wherein said monitoring is implemented intermittently.

28. The method of claim 24 wherein a pressure waveform of at least one of the left ventricle, the right atrium, and the left atrium is used instead of, or in conjunction with, that of the right ventricle.